Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression

Zhao,Yachao; Xiao,Zheng; Chen,Wenna; Yang,Jinsheng; Li,Tao; Fan,Bo

doi:10.3892/mmr.2015.3664

Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression

Authors:
- Yachao Zhao
- Zheng Xiao
- Wenna Chen
- Jinsheng Yang
- Tao Li
- Bo Fan
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Department of Neurology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: April 22, 2015 https://doi.org/10.3892/mmr.2015.3664
Pages: 2313-2322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas. Recently, disulfiram (DSF) has been shown to induce the loss of MGMT protein and increase TMZ efficacy in glioblastoma cells, while CD133+ nestin+ cells isolated from the cell population have been implicated as pituitary adenoma stem‑like cells. However, whether DSF is able to potentiate the cytotoxic effects of TMZ on human pituitary adenoma cells has not been investigated to date. In the present study, CD133+ nestin+ phenotype cells were isolated from primary cultured human pituitary adenoma cells using microbeads. It was found that DSF reduced MGMT protein expression and sensitized human pituitary adenoma cells and stem-like cells to TMZ in vitro, while the proteasome inhibitor PS-341 abrogated the inhibitory effect of DSF on MGMT in vitro. The sensitizing effect of DSF was also verified in primary cultured human pituitary adenoma cells in vivo. The results of the present study suggested that DSF can increase the efficacy of the anti-tumor effect of TMZ on human pituitary adenoma cells and CD133+ nestin+ stem like cells via the ubiquitin‑proteasomal MGMT protein elimination route. DSF combined with TMZ may be an effective therapeutic strategy against aggressive pituitary adenomas.

View Figures

View References

1	Beckers A: Higher prevalence of clinically relevant pituitary adenomas confirmed. Clin Endocrinol (Oxf). 72:290–291. 2010. View Article : Google Scholar
2	Tamer G, Telci A, Mert M, Uzum AK, Aral F, Tanakol R, Yarman S, Boztepe H, Colak N and Alagöl F: Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. 41:138–143. 2012. View Article : Google Scholar
3	Karavitaki N: Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris). 73:79–80. 2012. View Article : Google Scholar
4	Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary adenomas: a systematic review. Cancer. 101:613–619. 2004. View Article : Google Scholar : PubMed/NCBI
5	Selman WR, Laws ER Jr, Scheithauer BW and Carpenter SM: The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 64:402–407. 1986. View Article : Google Scholar : PubMed/NCBI
6	Scheithauer BW, Kovacs KT, Laws ER Jr and Randall RV: Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 65:733–744. 1986. View Article : Google Scholar : PubMed/NCBI
7	Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J and François P: Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary. 16:515–522. 2013. View Article : Google Scholar
8	Levy A: Pituitary disease: presentation, diagnosis and management. J Neurol Neurosurg Psychiatry. 75(Suppl 3): iii47–52. 2004. View Article : Google Scholar
9	Buchfelder M: Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 12:256–260. 2009. View Article : Google Scholar
10	Maïza JC and Caron P: Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options. Ann Endocrinol (Paris). 70(Suppl 1): 12–19. 2009.In French. View Article : Google Scholar
11	Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E and Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf). 65:552–553. 2006. View Article : Google Scholar
12	Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS and Lechan RM: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary. 10:81–86. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mohammed S, Kovacs K, Mason W, Smyth H and Cusimano MD: Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 64:E773–774; discussion E774. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB and Besser GM: The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 83:4233–4238. 1998. View Article : Google Scholar : PubMed/NCBI
15	Zhou PZ, Ma WC, Wang XJ, Cheng SW and Jiang S: Isolation and preliminary identification of stem-like cells in pituitary adenoma. Sichuan Da Xue Xue Bao Yi Xue Ban. 44:466–469. 2013.In Chinese. PubMed/NCBI
16	Raverot G, Sturm N and de Fraipont F: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 95:4592–4599. 2010. View Article : Google Scholar : PubMed/NCBI
17	Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr and Lopes MB: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O (6)-methylguanine meth-yltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 95:E280–290. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD and Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 115:261–262. 2008. View Article : Google Scholar
19	Chen W, Xiao Z, Zhao Y, Huang L and Du G: HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep. 30:2495–2501. 2013.PubMed/NCBI
20	Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC and Srivenugopal KS: Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis. 35:692–702. 2014. View Article : Google Scholar :
21	Xu Q, Yuan X, Tunici P, et al: Isolation of tumour stem-like cells from benign tumours. Br J Cancer. 101:303–311. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X and Shi H: Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
23	Xiao Z, Liu Q, Mao F, Wu J and Lei T: TNF-α-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas. Int J Mol Sci. 12:4165–4179. 2011. View Article : Google Scholar
24	Xiao Z, Liu Q, Zhao B, Wu J and Lei T: Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep. 26:1457–1464. 2011.PubMed/NCBI
25	Yang J, Xiao Z, Li T, Gu X and Fan B: Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int J Oncol. 40:1230–1237. 2012.
26	Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X and Shi H: Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
27	Chen W, Xiao Z, Zhao Y, Huang L and Du G: HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep. 30:2495–2501. 2013.PubMed/NCBI
28	O’Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 29A:940–942. 1993. View Article : Google Scholar
29	Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene. 23:2825–2837. 2004. View Article : Google Scholar : PubMed/NCBI
30	Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S and Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 8:2725–2734. 2002.PubMed/NCBI
31	Cen D, Brayton D, Shahandeh B, Meyskens FL Jr and Farmer PJ: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 47:6914–6920. 2004. View Article : Google Scholar : PubMed/NCBI
32	Cvek B: Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis and proteasome. Curr Cancer Drug Targets. 11:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
33	Triscott J, Lee C, Hu K, et al: Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 3:1112–1123. 2012.PubMed/NCBI
34	Johansson B: A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl. 369:15–26. 1992. View Article : Google Scholar : PubMed/NCBI
35	McCormack AI, McDonald KL, Gill AJ, et al: Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 71:226–233. 2009. View Article : Google Scholar
36	Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 4:296–307. 2004. View Article : Google Scholar : PubMed/NCBI
37	Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C and Knosp E: O (6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment. Cancer. 115:1070–1080. 2009. View Article : Google Scholar : PubMed/NCBI
38	Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J and Bartek J: Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets and DNA breakage. Mol Cell Biol. 25:3553–3562. 2005. View Article : Google Scholar
39	Sorensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J and Helleday T: The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 7:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
40	Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE and Stambrook PJ: The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene. 27:3977–3985. 2008. View Article : Google Scholar : PubMed/NCBI
41	Beck-Peccoz P, Lania A, Beckers A, Chatterjee K and Wemeau JL: 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2:76–82. 2013.2013. View Article : Google Scholar
42	Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD and Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol. 38:185–189. 2007. View Article : Google Scholar
43	Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, Larsson R and Lövborg H: Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol. 73:25–33. 2007. View Article : Google Scholar
44	Chen D, Cui QC, Yang H and Dou QP: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
45	Rizzoti K: Adult pituitary progenitors/stem cells: from in vitro characterization to in vivo function. Eur J Neurosci. 32:2053–2062. 2010. View Article : Google Scholar : PubMed/NCBI
46	Florio T: Adult pituitary stem cells: from pituitary plasticity to adenoma development. Neuroendocrinology. 94:265–277. 2011. View Article : Google Scholar : PubMed/NCBI
47	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
48	Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
49	Fernandez A, Karavitaki N and Wass JA: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 72:377–382. 2010. View Article : Google Scholar